The estimated Net Worth of Justin Burgess is at least $753 Mille dollars as of 15 February 2024. Mr Burgess owns over 6,667 units of Dynavax Technologies stock worth over $172,411 and over the last 5 years he sold DVAX stock worth over $581,053.
Mr has made over 12 trades of the Dynavax Technologies stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 20,526 units of DVAX stock worth $262,322 on 1 March 2024.
The largest trade he's ever made was selling 22,371 units of Dynavax Technologies stock on 27 February 2023 worth over $232,211. On average, Mr trades about 9,091 units every 65 days since 2020. As of 15 February 2024 he still owns at least 15,803 units of Dynavax Technologies stock.
You can see the complete history of Mr Burgess stock trades at the bottom of the page.
Justin Burgess is the Principal Accounting Officer & Controller at Dynavax Technologies.
Justin's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... e James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: